Skip to content

Study on 90% effective dose of cyclopofol combined in adult gastroscopy

Study on 90% effective dose of cyclopofol combined with sufentanil in adult gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062764
Enrollment
Unknown
Registered
2022-08-18
Start date
2022-08-18
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroscopy

Interventions

one:different doses of drugs

Sponsors

Zhejiang Provincial Tongde Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Perform gastroscopy; 2. Age 18-65 years old; 3. The American anesthesiologist association (ASA) is graded I-II; 4. Body mass index (body mass index, BMI) 18 ~ 28kg/m2.

Exclusion criteria

Exclusion criteria: 1. Patients with severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory infection, acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, etc.); 2. Evaluate patients with difficult airway (modified Mallampati score grade IV, restricted mouth opening, small mandible, nail-mental distance less than 6cm or less than three horizontal fingers of the examiner, etc.); 3. have a history of sleep apnea; 4. Patients with acute heart failure, unstable angina, and myocardial infarction within 6 months before screening; 5. Hemodynamic instability (systolic blood pressure [SBP] 180 mmHg, diastolic blood pressure DBP > 110 mmHg, peripheral blood oxygen saturation [SpO2] < 90%); 6. Liver dysfunction (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) higher than 2.5 times the upper limit of normal, total bilirubin (TBIL) higher than 1.5 times the upper limit of normal), or renal dysfunction ( Urea or urea nitrogen above the upper limit of normal, serum creatine above the upper limit of normal); 7. Patients with mental disorders (schizophrenia, mania, bipolar disorder, mental disorders, etc.), long-term use of psychotropic drugs, and cognitive dysfunction; 8. There is a history of long-term use of psychotropic or sedative-hypnotic drugs. 9. A history of drug abuse and drinking (alcohol abuse: an average daily consumption of more than 2 units of alcohol [1 unit = 360 ml of beer or 45 ml of 40% liquor or 150 ml of wine]); 10. Pregnant or breastfeeding women, or within 3 months of family planning (including men); 11. Allergies or contraindications to benzodiazepines, opioids, propofol and their components; 12. Patients who have participated in other drug trials within 3 months before the study.

Design outcomes

Primary

MeasureTime frame
ED90 of cyclopofol combined with sufentanil in adult gastroscopy;

Countries

China

Contacts

Public ContactWang hong wei

Zhejiang Provincial Tongde Hospital

wanghw@163.com+86 571 89972306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026